Does Presbyterian Healthcare Services Cover Dupixent?

What Is Dupixent and Why Does Coverage Get Complicated?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 and interleukin-13, two cytokines central to type-2 inflammatory disease. The FDA first approved dupilumab in March 2017 for moderate-to-severe atopic dermatitis in adults, and the label has since expanded to cover six additional indications across age groups ranging from 6 months to adult 1.

Coverage gets complicated for one structural reason. Dupixent's wholesale acquisition cost runs roughly $3,700 per month, placing it firmly in specialty-tier territory on almost every commercial formulary. Presbyterian Healthcare Services, like most regional insurers, applies additional utilization-management tools at that price point.

How Insurers Classify Specialty Biologics

Specialty biologics such as dupilumab are typically placed on Tier 4 or Tier 5 formulary tiers. At those tiers, cost-sharing under Presbyterian commercial plans may run 20 to 35% coinsurance after the deductible, which can translate to hundreds of dollars per fill even after manufacturer rebates are applied.

The FDA's current approved indications for dupilumab include 1:

• Moderate-to-severe atopic dermatitis (age 6 months and older)
• Moderate-to-severe asthma with eosinophilic phenotype (age 6 and older)
• Chronic rhinosinusitis with nasal polyps (age 18 and older)
• Eosinophilic esophagitis (age 12 and older, weight 40 kg or more)
• Prurigo nodularis (age 18 and older)
• Moderate-to-severe COPD with type-2 inflammation (age 18 and older, added June 2024)

Presbyterian will generally only authorize Dupixent for one of these labeled indications. Off-label requests face a substantially steeper documentation burden.

The Clinical Evidence Driving Prescriber Demand

Prescribers push hard for Dupixent because the evidence base is strong. In the SOLO-1 and SOLO-2 trials (combined N=1,379), dupilumab 300 mg every two weeks produced an IGA 0/1 response in 36 to 38% of patients with moderate-to-severe atopic dermatitis at week 16, versus 8 to 10% on placebo (P<0.001) 2. In LIBERTY ASTHMA QUEST (N=1,902), the 200 mg and 300 mg doses reduced annualized severe exacerbation rates by 47.7% and 48.0% respectively versus placebo 3.

Those numbers help explain why the American Academy of Dermatology and the Global Initiative for Asthma both list dupilumab as a preferred biologic in their current guidelines 4.

Presbyterian Healthcare Services: Plan Types and Formulary Basics

Presbyterian Healthcare Services is a New Mexico-based integrated health system and insurer. It operates several distinct plan lines: Presbyterian Commercial (employer-sponsored PPO and HMO products), Presbyterian Centennial Care (New Mexico Medicaid managed care), Presbyterian MediCare (Medicare Advantage), and Presbyterian Health Plan individual marketplace products.

Coverage rules for Dupixent differ meaningfully across these lines.

Commercial Plans

Presbyterian commercial plans use a standard specialty-tier structure. Dupixent appears on the formulary under the specialty-drug benefit, which typically requires members to use a designated specialty pharmacy. Prior authorization is required for all commercial plan members seeking dupilumab, regardless of diagnosis.

The specific clinical criteria Presbyterian commercial plans generally apply include:

• A confirmed diagnosis matching an FDA-approved indication
• Documentation that the disease is moderate-to-severe in classification
• Evidence of at least one adequate trial of a conventional therapy (for atopic dermatitis, this usually means a mid-to-high-potency topical corticosteroid for at least 4 weeks)
• A prescribing physician who is a board-certified specialist in the relevant field (dermatology, allergy/immunology, gastroenterology, or pulmonology)

Medicaid (Centennial Care)

Presbyterian Centennial Care administers New Mexico's Medicaid managed-care program. Federal Medicaid law requires coverage of all FDA-approved drugs when a state includes the drug's manufacturer in its rebate agreement, but managed-care plans retain the right to require prior authorization and impose preferred-drug-list requirements 5. Sanofi/Regeneron participates in the federal Medicaid Drug Rebate Program, so Dupixent is accessible through Centennial Care, but prior authorization and step therapy still apply. Cost-sharing for Medicaid members is limited by federal law, typically to nominal amounts (<$4 per fill for most members).

Medicare Advantage

Presbyterian MediCare (Medicare Advantage) plans cover Dupixent under the Part D specialty-drug benefit. The Medicare Prescription Payment Plan, which took effect in January 2025 under the Inflation Reduction Act, caps out-of-pocket drug costs at $2,000 per year for Medicare Part D enrollees 6. That cap meaningfully reduces Dupixent's financial burden for Medicare Advantage members compared to prior years. Note that the Dupixent MyWay manufacturer copay card cannot be used for Medicare or Medicaid-covered prescriptions.

Prior Authorization: What Presbyterian Requires

Prior authorization (PA) is the gate every Presbyterian member must pass before Dupixent is dispensed. The PA request is submitted by the prescribing clinician, not the patient, but patients who understand the requirements can help their providers build a stronger initial submission.

Standard PA Criteria for Atopic Dermatitis (the Most Common Indication)

Presbyterian's PA criteria for atopic dermatitis generally mirror the criteria published in the American Academy of Dermatology's 2023 atopic dermatitis guidelines 4, which state:

"Dupilumab is recommended for patients 6 months of age and older with moderate-to-severe atopic dermatitis that is not adequately controlled with topical therapies or when those therapies are not advisable."

To satisfy Presbyterian's PA process for atopic dermatitis, the prescriber's submission typically needs:

1. Diagnosis confirmation: ICD-10 code L20.x (atopic dermatitis), with disease-severity documentation (EASI, IGA, or SCORAD scoring preferred).
2. Step therapy evidence: Chart notes or pharmacy records showing a trial of a mid-to-high-potency topical corticosteroid (e.g., triamcinolone 0.1% or clobetasol 0.05%) for at least 4 weeks, with inadequate response or intolerance documented.
3. Specialist involvement: Office note from a board-certified dermatologist or allergist.
4. Pregnancy/contraindication screen: Documentation that topical calcineurin inhibitors (tacrolimus, pimecrolimus) were considered or trialed if appropriate.

PA Timelines

Federal and New Mexico state regulations require most non-urgent PA decisions within 3 business days. Urgent requests (when a delay would seriously jeopardize the patient's health) must be decided within 24 hours. Presbyterian's member handbook outlines these timelines, and members can request an expedited review by having their physician document clinical urgency.

Step Therapy for Other Indications

For asthma, Presbyterian typically requires a documented trial of an inhaled corticosteroid plus a long-acting beta agonist (ICS/LABA) at maximum tolerated doses before authorizing dupilumab. The Global Initiative for Asthma 2024 report designates biologics including dupilumab as Step 5 therapy, reserved for patients not controlled on high-dose ICS/LABA combinations 7.

For chronic rhinosinusitis with nasal polyps, Presbyterian generally requires prior intranasal corticosteroid use and specialist documentation of bilateral nasal polyps confirmed by nasal endoscopy or CT imaging.

What to Do If Presbyterian Denies Coverage

A denial is not a final answer. Presbyterian, like all New Mexico-licensed insurers, must offer a multi-level appeal process under the Affordable Care Act and New Mexico Insurance Code.

Level 1: Internal Appeal

File within the timeframe specified in the denial letter (typically 60 to 180 days depending on plan type). The prescribing physician should submit:

• A letter of medical necessity citing specific patient clinical data
• Peer-reviewed literature supporting dupilumab for the specific indication (the SOLO-1/SOLO-2 data for atopic dermatitis 2 and QUEST data for asthma 3 are directly relevant)
• Any available photographs documenting disease severity
• Documentation of all prior treatment failures

The insurer must issue an internal appeal decision within 30 days for standard appeals, or 72 hours for expedited appeals.

Level 2: External Independent Review

If the internal appeal fails, New Mexico law entitles members to an external review by an independent review organization (IRO) certified by the New Mexico Office of Superintendent of Insurance. External review decisions are binding on the insurer. External review is particularly powerful for step-therapy denials because New Mexico's Step Therapy Reform Law (enacted 2019) requires insurers to grant a step-therapy exception when the required drug is contraindicated, has been tried and failed, or would cause clinically significant harm [see New Mexico Statute 59A-22-52].

Peer-to-Peer Review

Before filing a formal appeal, the prescribing physician can request a peer-to-peer (P2P) call with the Presbyterian medical reviewer who issued the denial. P2P calls resolve a meaningful proportion of initial denials without a formal appeal. The physician should call Presbyterian's utilization management line within 1 to 3 business days of the denial to schedule the P2P.

Dupixent Costs and Patient Assistance Programs

Even with insurance, Dupixent's specialty-tier cost-sharing can be substantial. Several programs reduce or eliminate out-of-pocket costs for eligible patients.

Dupixent MyWay Copay Card

Sanofi and Regeneron operate the Dupixent MyWay program, which provides a manufacturer copay card for commercially insured patients. Eligible patients may pay as little as $0 per month, with the manufacturer covering up to $13,000 per year in copay costs. The program is available at dupixent.com/myway and requires enrollment before the first fill. Medicare and Medicaid members are not eligible for the copay card under federal anti-kickback regulations.

Patient Assistance Program (PAP)

For patients who are uninsured or whose income falls below 600% of the federal poverty level, the Dupixent MyWay Patient Assistance Program may provide Dupixent at no cost. Applications are processed through Sanofi's patient services team and require income documentation and proof of insurance status.

New Mexico Pharmaceutical Access Programs

New Mexico does not currently operate a state-level specialty-drug assistance program specifically covering biologics such as dupilumab. However, patients may access the NeedyMeds database and the Partnership for Prescription Assistance to identify additional funding sources.

Specialty Pharmacy Coordination

Presbyterian commercial plans typically require Dupixent to be dispensed through a contracted specialty pharmacy (commonly Accredo, CVS Specialty, or a Presbyterian-affiliated pharmacy). Using an out-of-network specialty pharmacy will often result in denial of the claim entirely, not just a higher copay. Confirming specialty pharmacy network status before the first fill prevents a common and costly error.

How Clinicians Can Optimize PA Submissions for Presbyterian

Incomplete or vague PA submissions are the leading cause of initial denials that would otherwise be approvable. The following practices improve first-pass approval rates.

Documentation Specificity

Vague language such as "patient failed topical steroids" is routinely insufficient. Presbyterian reviewers need:

• The specific drug name, strength, and vehicle (e.g., clobetasol propionate 0.05% cream)
• The duration of use (e.g., 6 weeks twice daily)
• The patient's response, documented with objective scoring (EASI dropped from 28 to 22, insufficient response)
• The reason for discontinuation if applicable (e.g., skin atrophy, patient intolerance)

Using Validated Severity Scores

The Eczema Area and Severity Index (EASI) and Investigator Global Assessment (IGA) are the scales most familiar to insurance reviewers because they appear in the key trials. An EASI score above 21.1 is classified as severe; scores of 7.1 to 21.1 indicate moderate disease 8. Submitting a scored EASI or IGA in the PA request signals clinical rigor and directly maps to the trial eligibility criteria Presbyterian reviewers use as reference.

Referencing Current Guidelines

The 2023 American Academy of Dermatology atopic dermatitis guideline 4 explicitly supports dupilumab as preferred systemic therapy. Citing specific guideline page numbers or recommendation grades in the PA letter strengthens the submission and reduces the likelihood of a medical-reviewer challenge.

Special Populations and Coverage Nuances

Pediatric Patients

The FDA approved dupilumab for atopic dermatitis in children as young as 6 months in 2022, based on the LIBERTY AD PRESCHOOL trial (N=162), which showed a 75% or greater improvement in EASI (EASI-75) in 53% of children aged 6 months to 5 years on dupilumab versus 11% on placebo (P<0.001) 9. Presbyterian commercial plans that cover adult dupilumab generally extend coverage to pediatric-labeled indications, but PA criteria for children may differ slightly, requiring a board-certified pediatric dermatologist or pediatric allergist note.

Pregnant and Breastfeeding Patients

The FDA Prescribing Information for dupilumab notes that available data from a pregnancy exposure registry are insufficient to establish drug-associated risk. The National Institute of Allergy and Infectious Diseases-sponsored PREG-DUPIX registry is ongoing 10. Clinicians managing pregnant patients with severe atopic dermatitis must weigh this uncertainty, and Presbyterian reviewers may request additional documentation of risk-benefit analysis for this population.

Off-Label Use

Presbyterian will not typically authorize Dupixent for off-label indications without a strong medical exception request supported by peer-reviewed literature and specialist attestation. The burden of proof for off-label requests is substantially higher than for labeled indications.

Frequently Asked Questions